These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33755163)

  • 1. Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020.
    Chen S; Li J
    JAMA Netw Open; 2021 Mar; 4(3):e212640. PubMed ID: 33755163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
    Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
    J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
    Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
    JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Between a rock and a hard place.
    Demaria AN
    J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials.
    Whyte J; Woodcock J; Wang J
    JAMA Intern Med; 2017 May; 177(5):724-727. PubMed ID: 28288256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs.
    Shahid I; Khan MS; Sohail A; Khan SU; Greene SJ; Fudim M; Michos ED
    JAMA Netw Open; 2022 Feb; 5(2):e220035. PubMed ID: 35212753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of Older People Reflective of Real-World Clinical Practice in Cardiovascular Drug Trials.
    Caughey GE; Inacio MC; Bell JS; Vitry AI; Shakib S
    J Am Heart Assoc; 2020 Nov; 9(21):e016936. PubMed ID: 33103558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
    Chang CY; Nguyen CP; Wesley B; Guo J; Johnson LL; Joffe HV
    N Engl J Med; 2020 Dec; 383(24):e131. PubMed ID: 33140923
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 11. U.S. to review drug intended for one race.
    Saul S
    N Y Times Web; 2005 Jun; ():A1, A15. PubMed ID: 15966118
    [No Abstract]   [Full Text] [Related]  

  • 12. Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006-2020.
    Shu M; Chen S; Li J
    J Gen Intern Med; 2022 Aug; 37(11):2888-2893. PubMed ID: 34704211
    [No Abstract]   [Full Text] [Related]  

  • 13. Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
    Greene MF; Klebanoff MA; Harrington D
    N Engl J Med; 2020 Dec; 383(24):e130. PubMed ID: 33140924
    [No Abstract]   [Full Text] [Related]  

  • 14. An analysis of FDA-approved drugs for cardiovascular diseases.
    Kinch MS; Surovtseva Y; Hoyer D
    Drug Discov Today; 2016 Jan; 21(1):1-4. PubMed ID: 25218930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
    Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process.
    Somberg JC; Borer JS
    Am J Ther; 1999 May; 6(3):175-8. PubMed ID: 10423661
    [No Abstract]   [Full Text] [Related]  

  • 17. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 18. Are surrogate markers adequate to assess cardiovascular disease drugs?
    Temple R
    JAMA; 1999 Aug; 282(8):790-5. PubMed ID: 10463719
    [No Abstract]   [Full Text] [Related]  

  • 19. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.